| Alma Criseida Berlingeri Ramos, MD | |
|
1367 Dominion Plz, Tyler, TX 75703 | |
| (903) 534-6200 | |
| (903) 939-0755 |
| Full Name | Alma Criseida Berlingeri Ramos |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 20 Years |
| Location | 1367 Dominion Plz, Tyler, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083818884 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 26080R (Puerto Rico) | Secondary |
| 207ND0900X | Dermatology - Dermatopathology | N3493 (Texas) | Secondary |
| 207N00000X | Dermatology | N3493 (Texas) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oliver Street 5.01(a) Inc | 0042464125 | 141 |
| Oliver Street 5.01(a) Inc | 0042464125 | 141 |
News Archive
The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form of breast cancer.
States that received funding from two obesity prevention programs founded by the U.S. Centers for Disease Control & Prevention implemented more than twice as many obesity-prevention policy initiatives as states that did not receive funding, according to a study by researchers from RTI International.
The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.
A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.
› Verified 8 days ago
| Entity Name | Utmb Faculty Group Practice |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241146 PECOS PAC ID: 3375456734 Enrollment ID: O20031112000438 |
News Archive
The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form of breast cancer.
States that received funding from two obesity prevention programs founded by the U.S. Centers for Disease Control & Prevention implemented more than twice as many obesity-prevention policy initiatives as states that did not receive funding, according to a study by researchers from RTI International.
The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.
A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.
› Verified 8 days ago
| Entity Name | Oliver Street 5.01(a) Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457695413 PECOS PAC ID: 0042464125 Enrollment ID: O20130128000189 |
News Archive
The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form of breast cancer.
States that received funding from two obesity prevention programs founded by the U.S. Centers for Disease Control & Prevention implemented more than twice as many obesity-prevention policy initiatives as states that did not receive funding, according to a study by researchers from RTI International.
The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.
A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alma Criseida Berlingeri Ramos, MD 1367 Dominion Plz, Tyler, TX 75703-1013 Ph: (903) 534-6200 | Alma Criseida Berlingeri Ramos, MD 1367 Dominion Plz, Tyler, TX 75703 Ph: (903) 534-6200 |
News Archive
The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
Researchers in the University of Delaware's Department of Biological Sciences are investigating a new drug that has shown positive results in early tests of its ability to fight a rare and aggressive form of breast cancer.
States that received funding from two obesity prevention programs founded by the U.S. Centers for Disease Control & Prevention implemented more than twice as many obesity-prevention policy initiatives as states that did not receive funding, according to a study by researchers from RTI International.
The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.
A new study shows a drug developed in conjunction with investigators at Indiana University School of Medicine to alleviate symptoms of a rare musculoskeletal condition is significantly more effective than conventional therapies.
› Verified 8 days ago
Shanna Burris Meads, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1367 Dominion Plz, Tyler, TX 75703 Phone: 903-534-6200 | |
Stephen John Beck, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 1367 Dominion Plz, Tyler, TX 75703 Phone: 903-534-6200 Fax: 903-939-0755 | |
Bradley Scott Graham, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1367 Dominion Plaza, Tyler, TX 75703 Phone: 903-534-6200 | |
Elizabeth Stripling Morris, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1367 Dominion Plaza, Tyler, TX 75703 Phone: 903-534-6200 | |
Lawrence Lazelle Anderson, MD Dermatology Medicare: Medicare Enrolled Practice Location: 1367 Dominion Plaza, Tyler, TX 75703 Phone: 903-534-6200 | |
Thomas Lambert Jr., MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5791 Copeland Rd, Tyler, TX 75703 Phone: 903-509-2020 |